• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to: 'Correspondence on 'Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort' by Micheroli by Huang .

作者信息

Ciurea Adrian, Micheroli Raphael

机构信息

Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland

Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland.

出版信息

Ann Rheum Dis. 2022 Nov;81(11):e227. doi: 10.1136/annrheumdis-2020-218832. Epub 2020 Sep 15.

DOI:10.1136/annrheumdis-2020-218832
PMID:32933922
Abstract
摘要

相似文献

1
Response to: 'Correspondence on 'Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort' by Micheroli by Huang .对米凯罗利（Micheroli）的《关于“瑞士临床质量管理队列中，既往使用过肿瘤坏死因子抑制剂的中轴型脊柱关节炎患者中，司库奇尤单抗与另一种肿瘤坏死因子抑制剂的疗效对比”的通信》的回复 作者：黄
Ann Rheum Dis. 2022 Nov;81(11):e227. doi: 10.1136/annrheumdis-2020-218832. Epub 2020 Sep 15.
2
Correspondence on 'Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort' by Micheroli .关于米凯罗利所著《司库奇尤单抗与另一种肿瘤坏死因子抑制剂在瑞士临床质量管理队列中既往接受过肿瘤坏死因子抑制剂治疗的中轴型脊柱关节炎患者中的疗效比较》的通信
Ann Rheum Dis. 2022 Nov;81(11):e226. doi: 10.1136/annrheumdis-2020-218779. Epub 2020 Sep 15.
3
Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort.在瑞士临床质量管理队列中，先前接受过 TNF 抑制剂治疗的轴性脊柱关节炎患者中，司库奇尤单抗与另一种 TNF 抑制剂的疗效比较。
Ann Rheum Dis. 2020 Sep;79(9):1203-1209. doi: 10.1136/annrheumdis-2019-215934. Epub 2020 Jun 24.
4
HLA-B27 as a predictor of effectiveness of treatment with TNF inhibitors in axial spondyloarthritis: data from the Swiss Clinical Quality Management Registry.HLA-B27 作为 TNF 抑制剂治疗轴性脊柱关节炎疗效的预测因子：来自瑞士临床质量管理登记处的数据。
Clin Rheumatol. 2023 May;42(5):1267-1274. doi: 10.1007/s10067-022-06490-8. Epub 2022 Dec 27.
5
Retention rate and effectiveness of secukinumab vs TNF inhibitor in ankylosing spondylitis patients with prior TNF inhibitor exposure.有既往 TNF 抑制剂暴露史的强直性脊柱炎患者中司库奇尤单抗与 TNF 抑制剂的保留率和疗效。
Rheumatology (Oxford). 2021 Dec 1;60(12):5743-5752. doi: 10.1093/rheumatology/keab245.
6
One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses.司库奇尤单抗与肿瘤坏死因子抑制剂治疗脊柱关节炎的一年疗效：来自五个北欧生物制剂登记处的结果，涵盖超过10,000个治疗疗程
Arthritis Care Res (Hoboken). 2022 May;74(5):748-758. doi: 10.1002/acr.24523. Epub 2022 Mar 8.
7
The Future of Axial Spondyloathritis Treatment.轴向型脊柱关节炎的治疗前景。
Rheum Dis Clin North Am. 2020 May;46(2):357-365. doi: 10.1016/j.rdc.2020.01.014.
8
Secukinumab in the treatment of psoriatic arthritis or ankylosing spondyloarthritis with multiple sclerosis: a case series with literature review.司库奇尤单抗治疗银屑病关节炎或强直性脊柱炎合并多发性硬化症：病例系列及文献综述
Immunotherapy. 2022 Apr;14(6):401-408. doi: 10.2217/imt-2021-0128. Epub 2022 Feb 14.
9
2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.2019 年美国风湿病学会/脊柱关节炎协会/脊柱关节炎研究和治疗网络关于治疗强直性脊柱炎和非放射学中轴型脊柱关节炎的建议更新。
Arthritis Rheumatol. 2019 Oct;71(10):1599-1613. doi: 10.1002/art.41042. Epub 2019 Aug 22.
10
Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study.肿瘤坏死因子抑制剂在银屑病关节炎和中轴型脊柱关节炎中的剂量调整（TAPAS）：一项回顾性队列研究。
Rheumatology (Oxford). 2022 May 30;61(6):2307-2315. doi: 10.1093/rheumatology/keab741.